Palifermin, the first specific drug treatment for oral mucositis in bone marrow transplant

Published: June 8, 2009
Abstract Views: 155
PDF: 266
Untitled (): 0
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Even though the target of chemotherapy and radiotherapy is the tumor cell, normal rapidly dividing tissues are affected and injuries of the upper and lower gastrointestinal tract are frequent. Oral mucositis (OM) is the most common complication following myeloablative therapy and Hematopoietic Stem Cell Transplantation (HSCT). Almost all patients receiving chemotherapy and radiotherapy treatment experience some degree of OM. In particular, about 40% of patients receiving standard chemotherapy, 75-90 % of bone marrow transplant patients treated with high-dose conditioning regimen and nearly all patients treated with radiotherapy for head and neck cancers develop OM.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Gallo, E. (2009). Palifermin, the first specific drug treatment for oral mucositis in bone marrow transplant. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.433